Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal.

ABSTRACT:

Background

The introduction of eculizumab has significantly improved the outcome of patients with atypical haemolytic uraemic syndrome (aHUS). Because of the risk of relapse after discontinuation, eculizumab was proposed as life-long therapy. However, data on the outcome of relapse are limited. In the Netherlands, patients with aHUS are treated with a restrictive eculizumab regime and are included in a national observational study (CUREiHUS, Dutch Trial Register NTR5988/NL5833).

Methods

For this interim safety analysis, we evaluated the outcome of all adult patients with a suspected relapse, defined as the need to intensify eculizumab after tapering or withdrawal of therapy.

Results

We describe 11 patients who received renewed eculizumab therapy because of suspected r

SUBMITTER: Duineveld C 

PROVIDER: S-EPMC8496203 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature